No Data
No Data
Investors Ignore Increasing Losses at Hebei Changshan Biochemical Pharmaceutical (SZSE:300255) as Stock Jumps 8.7% This Past Week
While Hebei Changshan Biochemical Pharmaceutical Co., Ltd. (SZSE:300255) shareholders are probably generally happy, the stock hasn't had particularly good run recently, with the share price falling 12
Hebei Changshan Biochemical Pharmaceutical (300255.SZ): Low molecular weight heparin preparation products, mainly sold domestically, with a low proportion of international exports.
Changshan Biochemical Pharmaceutical (300255.SZ) stated on its investor interaction platform on June 5th that the company's low molecular weight heparin products are mainly sold domestically and the international export sales ratio is not high, but the company regards heparin export as an important direction for future development. The company's heparin products have been registered abroad in the past two years, and the registration work for the company's heparin products in the EU and the United States is also actively being pushed forward.
Hebei Changshan Biochemical Pharmaceutical (300255.SZ): General manager changed to Gao Xiaodong.
On June 5th, Gelonhui reported that Hebei Changshan Biochemical Pharmaceutical Co., Ltd. (300255.SZ) announced that the board of directors of the company received the resignation letter from Ms. Cai Hao, the former general manager of the company. Due to personal reasons, Ms. Cai Hao applied to resign from the position of general manager of the company. After resigning, she will no longer hold any position in the company. In accordance with the needs of the company's development, and after passing the qualification examination of the nomination committee of the board of directors, the fifth board of directors of the company held its fifteenth meeting on June 5, 2024, and passed the "Proposal on the Appointment of General Manager", agreeing to appoint Mr. Gao Xiaodong as the general manager of the company, for the same term as this board of directors.
Changshan Biochemical Pharmaceutical Gets Nod to Market Enoxaparin Sodium Injection
Hebei Changshan Biochemical Pharmaceutical (SHE:300255) obtained approval from Chinese drug regulators to register and market enoxaparin sodium injection, according to the company's filing on the Shen
Hebei Changshan Biochemical Pharmaceutical (Stock Code: 300255.SZ): Enoxaparin Sodium Injection Obtained Drug Registration Certificate in Mali.
Changshan Biochemical Pharmaceutical (300255.SZ) announced on June 4th that the company recently received notice that its drug, Enaxoparin Sodium Injection, has obtained a drug registration certificate issued by the Malian drug regulatory authority. Enaxoparin Sodium Injection is used to prevent venous thromboembolic diseases (such as thrombus formation related to orthopedic or general surgery); treat established deep vein thrombosis with or without pulmonary embolism, without severe clinical symptoms, excluding pulmonary embolism requiring surgical or thrombolytic treatment; treat unstable angina and non-Q wave myocardial infarction in combination with aspirin; used for blood transfusion
Does Hebei Changshan Biochemical Pharmaceutical (SZSE:300255) Have A Healthy Balance Sheet?
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the permanent loss of capital.' When we think about how risky a company is, we always like
No Data